Robotic Surgery in China: Evidence and Surgeon Experience

Evaluate robotic surgery in China by procedure-specific evidence, surgeon and team experience, conversion planning, device limits, records and full cost.

Key takeaways

A surgical robot is an instrument system the surgeon drives from a console. Every movement and every decision stays with the surgeon [1].
There is no single procedure called “robotic surgery.” Evidence from prostate, rectal, cardiac, gynaecologic, thoracic, orthopaedic or neurosurgical operations cannot be pooled into one universal promise.
The comparison worth having is the same operation for the same indication: robotic versus conventional laparoscopy or open surgery, judged by the outcomes that matter to that patient.
A safe programme also needs an experienced bedside assistant, a practised anaesthesia and nursing team, working backup equipment and a rehearsed plan for undocking and conversion.

Full guide

The word “robot” can make a familiar operation sound like a different treatment entirely. It isn’t. The diagnosis and the surgical objective still come first: a prostate has to be removed with appropriate margins, a rectal tumour has to be dissected safely, a joint replacement has to be planned and implanted properly. The platform changes how the surgeon sees, reaches and guides instruments. Whether the indication is right and the result good still comes down to the operation itself.

The US FDA describes computer-assisted surgical systems as devices in which the surgeon directly controls the instruments from a console, and current systems do not perform surgery on their own [1]. Keep that in mind when a hospital advertises “AI surgery,” “intelligent surgery” or “one-click precision.” Ask what the software actually does: camera control, navigation, image registration, trajectory planning, instrument movement, or something else.

First identify the operation—not just the platform

Before comparing routes, write down one clear sentence:

The proposed operation is ___ for ___ disease, using ___ access, with ___ as the main clinical goal.

Then list the alternatives. For an abdominal or pelvic operation that usually means open surgery, conventional laparoscopy and robot-assisted laparoscopy. For an orthopaedic procedure, the system may guide alignment or bone preparation rather than move wristed instruments inside a body cavity. Neurosurgical and spinal systems tend to provide navigation or trajectory assistance. Each category solves a different technical problem, and none of them can borrow another’s evidence.

The model and version matter too. A multi-port soft-tissue platform, a single-port system and an orthopaedic robotic arm differ in instruments, approved uses, failure modes and training requirements. Confirm the exact registered device and its intended use in the hospital’s documents; a brand logo in a brochure tells you nothing.

Where the technology may help

Depending on the platform and the procedure, the genuinely useful features tend to be:

a magnified three-dimensional view of the operative field;
articulated instruments that reach angles straight laparoscopic tools cannot;
motion scaling and filtering of small hand tremor;
a stable camera under the operating surgeon’s own control;
navigation or planning that links imaging to the operative target;
better ergonomics for the surgeon during a long case.

These are technical advantages, and a technical advantage becomes a patient benefit only if it moves an outcome that matters: fewer complications, less blood loss or pain, shorter recovery, better function, better cancer control, fewer conversions or a more reliable implant position. Even then, the benefit is often modest and specific to that procedure.

What the system cannot remove

Robotic access changes none of the risks of the underlying operation. Bleeding, infection, anaesthetic complications, organ or nerve injury, thrombosis, leakage, urinary or sexual dysfunction, incomplete tumour removal and reoperation all stay on the table, in proportions that depend on the procedure.

The platform adds practical limits of its own:

docking and instrument exchange take time, especially while a team is early in its learning curve;
robotic arms and ports can collide, and access to the patient is more restricted once the system is docked;
many systems give limited or no natural tactile feedback, so the surgeon works mainly from vision and experience;
an equipment, image, instrument or power fault can force rapid troubleshooting or conversion;
steep positioning and prolonged pneumoperitoneum may affect the lungs, circulation, nerves, eyes or pressure injuries in susceptible patients;
disposable instruments and operating-room time add cost;
a plan that starts minimally invasive can still end as conventional laparoscopy or open surgery.

FDA post-market reports include mechanical, instrument and display problems, as well as injuries and deaths, although a report on its own does not establish that a device caused an event [1]. The sensible response is a specific failure and rescue plan for that platform, not a blanket fear of machines.

Read evidence by procedure and outcome

Results from one operation make a poor slogan for another. Two randomised trials show why.

In the ROLARR trial of rectal cancer surgery, conversion to open surgery occurred in 8.1% of robot-assisted cases and 12.2% of conventional laparoscopic cases, a difference that was not statistically significant. Circumferential margin positivity did not differ significantly either [5]. The trial does not prove that robots never help in rectal surgery; it shows that a plausible technical advantage failed to turn into a clear overall trial advantage.

A more recent randomised trial compared robot-assisted with open radical prostatectomy and found less blood loss and a shorter hospital stay on the robotic route, plus some advantages in functional recovery. Ninety-day complication rates were not significantly different, and cancer outcomes were comparable at 36 months [6]. Note what was actually compared: robotic versus open, not robotic versus conventional laparoscopy. Exporting those findings to other cancers would be a mistake.

A systematic review of randomised trials across several operations reached a similar conclusion: the answer depends on the procedure and the endpoint you pick [7]. So when a hospital says its results are “better,” ask for the actual denominator, comparator, time point and definition.

The patient’s anatomy still decides much of the plan

Suitability can turn on tumour size and local invasion, previous operations, adhesions, prior radiotherapy, body habitus, cardiopulmonary reserve, bleeding risk, infection, joint or spine mobility and the ability to tolerate the required position. With cancer, the neoadjuvant treatment, the lymph-node plan, the margin strategy and the possible removal of adjacent organs usually matter more than which machine is in the room.

Difficult anatomy does not automatically argue for a robot. Articulation and visualisation may help, or the case may call for faster open access and a different team. The operating surgeon should explain why this route fits this patient; reciting the robot’s general capabilities is no answer.

Ask about the surgeon’s exact experience

“Our centre has done 10,000 robotic procedures” tells you almost nothing about the person operating tomorrow. Ask the lead surgeon directly:

How many of this exact procedure have you done robotically, and how many in the past 12 months?
How many of those patients had a similar disease stage or complexity?
Which platform and model were used, and will you be at the console for the key steps?
Where are you on the learning curve for this operation? Was proctoring required or recently completed?
What are your conversion, major complication, readmission and reoperation rates, with denominators and follow-up periods?
For cancer, what are the relevant margin, node-yield, recurrence or functional results?
Who takes over if you become unavailable during the case?

Good surgeons may not have a glossy dashboard, but they can describe their own practice honestly and set it against the published evidence. A surgeon who will not define “success” or say who performs the critical steps is more worrying than a missing round marketing number.

Experience belongs to the whole operating room

Once the surgeon sits down at the console, the person with immediate access to the patient is the bedside assistant. That assistant exchanges instruments, suctions, retracts, clips, controls bleeding, removes specimens and helps undock. Anaesthesiologists manage the physiological effects of position and insufflation while access to the airway or the patient is limited. Scrub nurses, circulating nurses, sterile-processing staff and biomedical engineers keep the instruments and the system ready.

Ask whether the same core team does this operation together regularly. Confirm that conventional laparoscopic and open instruments are already in the room, that blood and critical care are available when indicated, and that a qualified surgeon can operate at the bedside during an emergency. A new machine inside a highly experienced hospital is still not an established robotic programme for the proposed operation.

China’s rules focus on institutional and professional responsibility

China’s medical-technology management measures require medical institutions to maintain technology catalogues, surgical grading, professional authorisation, quality control, records and dynamic evaluation [2]. The National Health Commission’s standard for artificial-intelligence-assisted treatment technology sets institutional, departmental, equipment, personnel and quality-management conditions for robot-assisted surgery [3]. Separate surgical grading rules require ongoing assessment of a surgeon’s technical ability, safety, perioperative management and communication [4].

For you as a patient, the practical questions are:

Is the hospital authorised and equipped for this technology and this operation?
Does the named surgeon currently hold authorisation for this grade and procedure?
What training and supervised cases were completed on this exact platform?
How are complications, conversions, device problems and outcomes reviewed?

Regulatory compliance is a safety floor. It says nothing about which hospital or brand produces the best outcomes.

Conversion is a safety option, not automatically a failure

Conversions happen for many reasons: bleeding, adhesions, unexpected anatomy, tumour extent, anaesthetic instability, equipment failure or an inability to progress safely. In the consent discussion, make sure the team distinguishes conversion to conventional laparoscopy from conversion to open surgery.

Ask how the team will undock, how quickly the patient can be accessed, which surgeon will perform the alternative approach and whether the required instruments are already sterile and available. Also ask what conversion does to incision size, recovery, hospital stay and cost. A team that converts early for safety may be exercising good judgement; what you want to know is whether it recognised the problem and responded effectively.

Compare complete costs

Obtain an itemised estimate covering:

surgeon, anaesthesia and hospital charges;
the robotic platform or service fee;
disposable and limited-use instruments;
imaging, navigation, implants or pathology;
expected operating-room and inpatient time;
intensive care or higher-dependency care when relevant;
conversion, transfusion, complication or readmission costs;
follow-up, rehabilitation and management of catheters, drains or stomas.

A shorter stay can offset part of a higher theatre cost, but the hospital should show that using its own expected pathway. Comparing only the device surcharge against only the advertised benefit tells you very little.

Leave with an operation record that another doctor can use

Request the operative note, anaesthesia record, discharge summary, pathology report, implant or device record and complication plan. The operative note should identify the approach, platform/model, ports or access, important findings, major steps, specimens, implants or stapling devices, blood loss, complications and whether conversion occurred. For cancer, preserve the full pathology report and relevant imaging.

Back home, the local clinician needs ordinary clinical facts, not a certificate saying “successful robotic surgery.” Severe breathing difficulty, chest pain, fainting, heavy bleeding, worsening abdominal pain with fever, sudden weakness or confusion — any of these requires immediate local assessment.

Medical disclaimer: This guide is meant to support questions and record review; it does not recommend a platform or surgical route. The appropriate operation depends on diagnosis, anatomy, alternatives, surgeon and team capability, and informed consent.

FAQ

Is robotic surgery performed by artificial intelligence?

No. In the computer-assisted systems in use today, the surgeon controls the instruments. Software can support imaging, navigation or motion, but it does not take over the surgeon’s clinical judgement or responsibility.

Is robotic surgery always safer than open surgery?

No. Some procedures show advantages in selected outcomes, while other randomised comparisons find little or no significant difference. Safety comes down to the exact operation, the patient, the comparator and the team.

How many cases should a robotic surgeon have performed?

There is no universal number that fits every procedure. Ask about recent experience with the exact operation and platform, where the surgeon sits on the learning curve, what supervised training was completed, and the procedure-specific outcomes.

Does conversion to open surgery mean the operation went wrong?

Not necessarily. Conversion can be the safest response to bleeding, adhesions, unexpected anatomy, disease extent or device problems. What matters is whether the team anticipated it and could convert promptly.

What should I compare if robotic surgery costs more?

Compare the total expected cost and the outcomes that matter to you: complications, blood loss, pain, hospital stay, functional recovery, cancer control, conversion and possible readmission. The technology fee on its own tells you little.

Robotic Surgery in China: Benefits, Limits, and Surgeon Experience